These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

746 related items for PubMed ID: 18632907

  • 1. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM, Elizondo M, Ayala J.
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [Abstract] [Full Text] [Related]

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC.
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT, Findik D, Senkeles C, Arslan U.
    Ann Clin Microbiol Antimicrob; 2016 May 31; 15(1):36. PubMed ID: 27245756
    [Abstract] [Full Text] [Related]

  • 6. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
    Samra Z, Yardeni M, Peled N, Bishara J.
    Eur J Clin Microbiol Infect Dis; 2005 Sep 31; 24(9):592-5. PubMed ID: 16172856
    [Abstract] [Full Text] [Related]

  • 7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec 31; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 8. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S.
    J Antimicrob Chemother; 2004 Feb 31; 53(2):283-9. PubMed ID: 14688039
    [Abstract] [Full Text] [Related]

  • 9. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM, Reviákina V, Dolande M, Selgrad S.
    Med Mycol; 2009 Mar 31; 47(2):137-43. PubMed ID: 18651308
    [Abstract] [Full Text] [Related]

  • 10. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
    Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA, SENTRY Participant Group.
    J Clin Microbiol; 2001 Sep 31; 39(9):3254-9. PubMed ID: 11526159
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
    Arikan S, Sancak B, Hascelik G.
    Med Mycol; 2005 Mar 31; 43(2):171-8. PubMed ID: 15832560
    [Abstract] [Full Text] [Related]

  • 12. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
    Ko KS, Lee JY, Song JH, Peck KR.
    J Korean Med Sci; 2010 Dec 31; 25(12):1722-6. PubMed ID: 21165285
    [Abstract] [Full Text] [Related]

  • 13. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.
    Guinea J, Zaragoza Ó, Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M, CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI.
    Antimicrob Agents Chemother; 2014 Dec 31; 58(3):1529-37. PubMed ID: 24366741
    [Abstract] [Full Text] [Related]

  • 14. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC, Chen YH, Chen YC, Lu PL.
    Kaohsiung J Med Sci; 2012 Jun 31; 28(6):306-15. PubMed ID: 22632885
    [Abstract] [Full Text] [Related]

  • 15. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC, Gil J, Ramírez de Ocáriz I, Benito R, Rezusta A.
    Rev Esp Quimioter; 2003 Jun 31; 16(2):227-32. PubMed ID: 12973462
    [Abstract] [Full Text] [Related]

  • 16. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA.
    Int J Antimicrob Agents; 2020 Jan 31; 55(1):105799. PubMed ID: 31520783
    [Abstract] [Full Text] [Related]

  • 17. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
    Lindberg E, Hammarström H, Ataollahy N, Kondori N.
    Sci Rep; 2019 Mar 07; 9(1):3838. PubMed ID: 30846717
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D, Watelle M, Nolard N.
    Rev Iberoam Micol; 2005 Mar 07; 22(1):24-8. PubMed ID: 15813679
    [Abstract] [Full Text] [Related]

  • 19. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA.
    Oral Microbiol Immunol; 2005 Dec 07; 20(6):349-53. PubMed ID: 16238594
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.